arrow
M

Marco Tagliamento

irccs policlinico gemelli
H指数:33
被引数:3,337

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Efficacy of Alectinib for ALK-positive NSCLC According to Tumor Burden and Body Mass Index: a Pooled Analysis of the Randomized Phase III Trials ALEX and J-ALEX

根据肿瘤负荷和体重指数评估阿来替尼对ALK阳性NSCLC的疗效:ALEX和J-ALEX随机III期试验的合并分析

2026-06-050
OAAI
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis

局部消融疗法(LAT)与表皮生长因子受体酪氨酸激酶抑制剂(TKIs)在晚期EGFR阳性非小细胞肺癌(NSCLC)中的首线整合:一项系统评价和荟萃分析

2026-04-210
OAAI
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses

可切除非小细胞肺癌的免疫疗法:新辅助/围手术期治疗继之以手术优于手术继之以辅助治疗。系统评价与Meta分析及亚组分析

2025-09-050
OAAI
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer

分子肿瘤委员会:国际肺癌研究协会的共识声明

2025-07-070
PRE
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer

DNA甲基转移酶3A(DNMT3A)突变与非小细胞肺癌中PD-(L)1阻断疗法的疗效

2025-06-180
PRE
Time to access to diagnosis and treatment for lung cancer (LC): Experience within an Italian comprehensive cancer center

肺癌(LC)诊断和治疗的可及性时间:意大利综合癌症中心的经验

2024-09-010
PRE
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
2024-08-064
OAAI
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024-08-012
OAAI
Impact of Body Mass Index (BMI) on the efficacy of different adjuvant chemotherapy schedules in patients with breast cancer: analysis from the randomized phase III GIM2 trial
2024-05-020
PRE
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
2024-05-014
PRE
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

癌症患者中TP53和DNA损伤基因的液体活检突变的基因组景观

2024-02-263
OA
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
2024-02-166
OAAI
Unraveling resistance and optimizing treatment through molecular profiling in patients with NSCLC and oncogenic fusions
2023-12-010
PRE
Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors
2023-12-010
PRE